Welcome to our dedicated page for Sunshine Biopharma news (Ticker: SBFM), a resource for investors and traders seeking the latest updates and insights on Sunshine Biopharma stock.
Sunshine Biopharma Inc. (NASDAQ: SBFM) generates news across commercial pharmaceuticals, biosimilars, and biotechnology research. Through its Canadian subsidiary Nora Pharma Inc., the company announces launches and regulatory milestones for generic prescription drugs and biosimilars in Canada, while its internal pipeline produces updates on mRNA-based oncology candidates and antiviral small-molecule programs.
Readers following SBFM news can expect coverage of generic drug launches in key therapeutic categories. Recent announcements include the commercialization of gabapentin for neuropathic pain and epilepsy, doxycycline for a range of bacterial and tick-borne infections, pravastatin for cholesterol management and cardiovascular risk reduction, and domperidone for nausea, vomiting, and gastrointestinal motility, including chemotherapy-induced nausea and vomiting. These items often highlight Health Canada authorizations, product indications, dosage forms, and Sunshine Biopharma’s growing catalog of more than 70 generic prescription drugs in Canada.
News flow also covers Sunshine Biopharma’s entry into biosimilars with NIOPEG, a biosimilar comparable to NEULASTA (pegfilgrastim) used to reduce infection risk in cancer patients receiving chemotherapy. Articles describe the significance of this launch for the company’s presence in the biologics market and its focus on oncology-related supportive care.
On the research side, Sunshine Biopharma issues updates on its K1.1 mRNA liver cancer program and its PLpro protease inhibitor program for SARS coronavirus infections, including preclinical data, collaborations with the University of Arizona, and publication of results in scientific journals. Additional corporate news may address treasury and capital allocation decisions, such as the board-approved $5 million strategic reserve allocation to Bitcoin, as well as commentary on the company’s broader strategy combining generics, biosimilars, and proprietary R&D.
For investors and observers, the SBFM news page offers a consolidated view of product launches, regulatory clearances, scientific milestones, and financial strategy updates. It is a useful resource for tracking how Sunshine Biopharma’s commercial activities and research programs evolve over time.
Sunshine Biopharma Inc. (OTC PINK:SBFM) announced it has secured a second tranche of funding totaling $550,000 from RB Capital Partners under a $2 million financing agreement. The funds will support the development of its Coronavirus treatment and the clinical development of Adva-27a, its lead anticancer drug. SBFM-PL4, a lead compound targeting Coronavirus proteases, is currently progressing through testing phases in collaboration with the University of Georgia. The company is also conducting trials for Adva-27a aimed at treating multidrug-resistant cancers, including pancreatic cancer.
Sunshine Biopharma (OTC PINK:SBFM) announced a collaboration with the University of Georgia to advance its SBFM-PL4 anti-coronavirus compound. The agreement aims to evaluate SBFM-PL4, a protease inhibitor targeting SARS-CoV-2, through in vitro tests, followed by cell culture and animal trials before human clinical testing. This partnership is focused on developing new treatments for COVID-19, which has significantly impacted global health. Sunshine is also developing its anticancer drug, Adva-27a, targeting multidrug-resistant cancer cells.
Sunshine Biopharma Inc. (OTC PINK:SBFM) has identified a lead compound from its library of Coronavirus protease inhibitors following screening at the University of Georgia. This lead compound targets SARS-CoV-2's papain-like protease, which is essential for viral replication. The company plans to proceed with in vitro tests to evaluate the compound's efficacy against COVID-19. Sunshine is also developing Adva-27a, an anti-cancer drug effective against resistant cancer cells, with trials planned at McGill University.
Sunshine Biopharma (OTC PINK:SBFM) announced it has received the first tranche of $250,000 from a financing agreement with RB Capital Partners to secure a minimum of $2 million. The funding will aid in the development of a Coronavirus treatment and the anticancer compound Adva-27a targeting pancreatic cancer. The convertible promissory notes will have a 5% interest rate and a maturity date of two years, convertible to shares at $0.30 or market value, whichever is higher. The clinical trials for Adva-27a are planned at McGill University.
Sunshine Biopharma (OTC PINK:SBFM) has successfully synthesized four potential inhibitors targeting the Coronavirus protease, a crucial component for the virus's replication. This advancement stems from a recently filed patent for small molecules aimed at treating Coronavirus infections, including COVID-19. The next steps involve analyzing the binding affinity of these compounds to the SARS-CoV-2 papain-like protease, selecting a lead candidate for further development. Sunshine is also advancing its anticancer drug, Adva-27a, which has shown effectiveness against multidrug-resistant cancer cells.